Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived Anti-CD123 CAR-T for Relapsed AML
NCT03114670Phase 1Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART123 in acute myeloid leukemia (AML), sponsored by Academy of Military Medical Sciences. Primary endpoint: Incidence of adverse events related to treatment at 15 years. Status: unknown.
02
Drugs
CART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03114670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114670.